414 related articles for article (PubMed ID: 7907610)
1. p53, c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas.
Korkolopoulou P; Oates J; Kittas C; Crocker J
J Clin Pathol; 1994 Jan; 47(1):9-14. PubMed ID: 7907610
[TBL] [Abstract][Full Text] [Related]
2. A comparative assessment of proliferating cell nuclear antigen, c-myc p62, and nucleolar organizer region staining in non-Hodgkin's lymphomas: a histochemical and immunohistochemical study of 200 cases.
Korkolopoulou P; Patsouris E; Pangalis G; Tsenga A; Elemenoglou J; Thomas-Tsangli E; Spandidos D; Kittas C
Hum Pathol; 1993 Apr; 24(4):371-7. PubMed ID: 7684020
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of proliferating cell nuclear antigen (PCNA), AgNORs and P53 in non-Hodgkin's lymphomas.
Korkolopoulou P; Angelopoulou MK; Kontopidou F; Tsengas A; Patsouris E; Kittas C; Pangalis GA
Leuk Lymphoma; 1998 Aug; 30(5-6):625-36. PubMed ID: 9711925
[TBL] [Abstract][Full Text] [Related]
4. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas.
Pagnano KB; Vassallo J; Lorand-Metze I; Costa FF; Saad ST
Am J Hematol; 2001 Jun; 67(2):84-92. PubMed ID: 11343379
[TBL] [Abstract][Full Text] [Related]
5. MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas.
Pich A; Ponti R; Valente G; Chiusa L; Geuna M; Novero D; Palestro G
J Clin Pathol; 1994 Jan; 47(1):18-22. PubMed ID: 7907607
[TBL] [Abstract][Full Text] [Related]
6. P 53 and PCNA in Non Hodgkin's lymphoma--an immunohistochemical evaluation.
Burra U; Shanthi P; Krishnan KB; Madhavan M
Indian J Pathol Microbiol; 2000 Jan; 43(1):61-4. PubMed ID: 12583422
[TBL] [Abstract][Full Text] [Related]
7. p53 expression in oat and non-oat small cell lung carcinomas: correlations with proliferating cell nuclear antigen.
Korkolopoulou P; Oates J; Crocker J; Edwards C
J Clin Pathol; 1993 Dec; 46(12):1093-6. PubMed ID: 7904273
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of cellular proliferative activity in 35 T-cell non-Hodgkin's lymphomas. Use of proliferating cell nuclear antigen and Ki-67 (MIB-1) antibodies and nucleolar organizer regions.
Caulet-Maugendre S; Patey M; Granier E; Joundi A; Gentile A; Caulet T
Anal Quant Cytol Histol; 1996 Oct; 18(5):337-44. PubMed ID: 8908304
[TBL] [Abstract][Full Text] [Related]
9. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.
Møller MB; Nielsen O; Pedersen NT
Histopathology; 2002 Oct; 41(4):322-30. PubMed ID: 12383214
[TBL] [Abstract][Full Text] [Related]
10. Correlation between PCNA and AgNOR scores in non-Hodgkin's lymphomas using sequential staining technique.
Smith FG; Murray PG; Crocker J
J Clin Pathol; 1993 Jan; 46(1):28-31. PubMed ID: 8094401
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis and proliferative activity of non-Hodgkin's lymphomas: comparison with expression of bcl-2, p53 and c-myc proteins.
Takano Y; Saegusa M; Ikenaga M; Okayasu I
Pathol Int; 1997; 47(2-3):90-4. PubMed ID: 9088026
[TBL] [Abstract][Full Text] [Related]
12. Proliferating cell nuclear antigen (PCNA) in non-Hodgkin's lymphomas: correlation with working formulation and Kiel classification in formalin-fixed paraffin-embedded material.
Rabenhorst SH; Burini RC; Schmitt FC
Pathology; 1996 Jan; 28(1):12-6. PubMed ID: 8714262
[TBL] [Abstract][Full Text] [Related]
13. c-Myc oncogene and Cdc25A cell activating phosphatase expression in non-Hodgkin's lymphoma.
Aref S; Fouda M; El-Dosoky E; Menessy A; Mabed M; Saleeb M; Zalata K
Hematology; 2003 Jun; 8(3):183-90. PubMed ID: 12745652
[TBL] [Abstract][Full Text] [Related]
14. DNA image cytometry and the expression of proliferative markers (proliferating cell nuclear antigen and Ki67) in non-Hodgkin's lymphomas.
Czader M; Porwit A; Tani E; Ost A; Mazur J; Auer G
Mod Pathol; 1995 Jan; 8(1):51-8. PubMed ID: 7731942
[TBL] [Abstract][Full Text] [Related]
15. The expression of myc and ras oncogene protein in childhood lymphomas.
Sakalidou A; Kanavaros P; Tzardi M; Kalmanti M
Anticancer Res; 1996; 16(1):487-91. PubMed ID: 8615659
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas--an enhanced immunohistochemical approach.
Saegusa M; Takano Y; Kishimoto H; Wakabayashi G; Nohga K; Okudaira M
J Cancer Res Clin Oncol; 1993; 119(12):737-44. PubMed ID: 8104947
[TBL] [Abstract][Full Text] [Related]
17. Localization of proliferating cell nuclear antigen (PCNA/Cyclin) in workshop cases of Hodgkin's disease and non-Hodgkin's lymphoma.
Kamel OW; Warnke RA; Banks PM
Semin Diagn Pathol; 1992 Nov; 9(4):311-4. PubMed ID: 1362284
[TBL] [Abstract][Full Text] [Related]
18. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in non-Hodgkin's lymphoma.
Klemi PJ; Alanen K; Jalkanen S; Joensuu H
Br J Cancer; 1992 Oct; 66(4):739-43. PubMed ID: 1358164
[TBL] [Abstract][Full Text] [Related]
19. DNA content and expression of PCNA and p53 in Hodgkin's disease and Hodgkin's-like B-cell lymphoma.
Czader M; Porwit A; Ost A; Auer G
APMIS; 1994 Nov; 102(11):865-73. PubMed ID: 7833007
[TBL] [Abstract][Full Text] [Related]
20. Proliferative activity in non-Hodgkin's lymphomas. A comparison of the bromodeoxyuridine labeling index with PCNA immunostaining and quantitative image analysis.
Sebo TJ; Roche PC; Witzig TE; Kurtin PJ
Am J Clin Pathol; 1993 Jun; 99(6):668-72. PubMed ID: 8100680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
